Specific NF-B/Rel proteins regulate murine dendritic cell (DC) survival, differentiation, and activation, but little is known of their role in human cells because of limited loss-of-function analyses. RNA interference (RNAi) is a mechanism to effectively silence gene expression via sequence-specific double-stranded small interfering RNAs (siRNAs). RNAi was used to assess the role of the p50 (NF-B1) protein in the maturation and activation of cultured human monocyte-derived DC (MoDC). Transfection of cultured MoDC with siRNAs reduced p50 mRNA and protein levels in a specific, dose-dependent, and time-dependent manner. Basal or maturation-induced expression of HLA-DR and costimulatory molecules were not affected, whereas transcription of the IL-12 p40 gene and the secretion of IL-12␣␤ were reduced. Such MoDC induced less IFN-␥ production by T cells in MLR. This is the first report of RNAi-induced phenotype in human primary DC with a method that caused no measurable toxicity or type-I IFN response. siRNAs appear useful for the study of signaling pathways in immune cells, revealing a pivotal requirement for p50 in MoDC for IL-12 production and induction of optimal type-1 immune responses.
D endritic cells (DC) 3 constitute a complex system of APC that induce immunity or tolerance and play prominent roles in infectious diseases, immune disorders, and vaccination. One property of DC is to effectively interact with and present Ags to naive T cells (1, 2) . Such T cell-stimulating ability is regulated by various states of DC activation in response to complex environmental cues. Signals from pathogens, proinflammatory mediators, or T cell products such as CD40 ligand (CD40L) promote a highly immunogenic state in DC by up-regulating levels of MHC class II Ags and T cell costimulatory receptors on the membrane, and by inducing the production of proinflammatory cytokines such as IL-12. Yet, there is limited understanding of the molecular mechanisms regulating these processes, thus limiting interventions on immune responses.
Ligands of the TNF-or Toll-like/IL-1 families of receptors are prominent regulators of DC activation. Like many proinflammatory agents, these signals converge onto the activation of NF-B/ Rel proteins for the transcription of target genes, for instance IL-12␤ or MHC class II chains. In mammalian cells, NF-B/Rel proteins consist of p50 (NF-B1 and its precursor p105), p52 (NF-B2 and its precursor p100), p65 (RelA), RelB, and cRel that are encoded by different genes and regulate response to stress, inflam-mation, apoptosis, immunity, and cellular development (recently reviewed in Refs. 3 and 4) . Targeted mutations in mice show that deficits in RelB, cRel, p50, or p52 lead to various immune impairments (5) (6) (7) (8) that directly implicate DC. RelB, is preferentially expressed in the CD8␣ Ϫ subset of murine DC and is essential for the development of this cell type (9) . Single deficiencies in p50, cRel, or RelA do not impair DC development, but combined deficiencies that include p50 have major and specific impacts (10) . Mice lacking both p50 and RelA lack all CD11c ϩ DC subsets. The combined lack of p50 and cRel impairs DC function, reducing survival in response to CD40L, decreasing basal levels of MHC class II Ags, and decreasing the ability to produce IL-12. Thus, p50 in association with partners is a pivotal element in the hematopoietic and functional development of murine DC.
Human blood monocyte-derived DC (MoDC) are extensively used as models of Ag presentation and are developed as clinical vaccines in a variety of immunotherapy settings (11) . Signaling pathways have not been fully characterized in these cells for which a murine equivalent cell type has not been extensively studied. Descriptive studies, analysis of pro-inflammatory responses, and blocking studies have concurred to demonstrate that the NF-B signaling pathway is globally important in MoDC and regulates their functional maturation and activation (12) (13) (14) (15) . However, ascribing specific roles for any constituent of the family, particularly p50, has not yet been done because of the lack of loss-of-function analyses.
RNA interference (RNAi) is a mechanism for sequence-specific posttranscriptional inhibition of gene expression via doublestranded RNA molecules. Initially described in plants, worms, Drosophila, and parasites (reviewed recently in Refs. 16 -18) , RNAi has recently been applied to mammalian cells with the use of small interfering RNAs (siRNAs) (19 -21) . These intermediate products result from the cleavage of double-stranded RNA and consist of 21-23 nt-long RNA duplex effector molecules able to recognize and to guide the degradation of complementary mRNA sequences. Recent studies have described RNAi following transfection of chemically synthesized siRNAs in cultured mammalian cells, causing inhibition of a variety of reporter, endogenous, or infectious gene products (20, (22) (23) (24) (25) . At present, it is not known whether this technique can be effectively applied to regulate gene expression in primary human DC.
In this study we report that RNAi is feasible in primary human MoDC and can be used to specifically knock down the expression of p50, revealing its role in the production of IL-12 and induction of optimal type-1 T cell response, but not in the up-regulation of cell surface molecules on DC.
Materials and Methods

Source of cells
G-CSF-mobilized peripheral blood and umbilical cord blood samples were obtained from Gustave Roussy Institute (Villejuif, France) or Tenon Hospital (Paris, France) in accordance with institutional guidelines. Mononuclear cells (MNC) were isolated by centrifugation over Ficoll (Amersham Pharmacia Biotech, Piscataway, NJ), and when needed they were cryopreserved in liquid nitrogen using a 10% DMSO solution.
Culture of DC
Adherent monocytes were obtained by incubating MNC onto plastic (2 ϫ 10 6 cells/ml/well in 24-well tissue culture plates) in RPMI medium with 10% FBS and antibiotics (R10) (26) in a humidified atmosphere at 37°C, 5% CO 2 for 2 h. Nonadherent cells were removed by washing, and R10 medium containing GM-CSF (25 ng/ml; Immunex, Seattle, WA) and IL-4 (10 ng/ml; R&D Systems, Minneapolis, MN) was added for 4 days to produce immature DC.
siRNAs and electroporation
The 21-nt-long interfering RNA duplexes with two 3Ј-end overhang dT nucleotides in the antisense strand were synthesized as reported (20, 22) . The sequences of the antisense strands of the siRNAs were as follows: anti-p50 siRNA: 5Ј-AGU CCA GGA UUA UAG CCC CdTdT (MWG Biotec, Ebersberg, Germany or Dharmacon, Lafayette, CO); control I-siRNA, an irrelevant siRNA with random nucleotides and no known specificity: 5Ј-ACG GGG GGC CCU UAA AAC AdTdT (MWG Biotec); and control II-siRNA, an irrelevant siRNA with random nucleotides and a GC ratio close to that of anti-p50 siRNA: 5Ј-UGU UUU AAG GGC CCC CCG UdTdT (Dharmacon and Genset, Evry, France). Transfection of siRNAs was conducted by electroporation using an ECM 830 square wave electroporation system (BTX, San Diego, CA). Briefly, 4 ϫ 10 5 cells were washed twice in PBS and placed in 4-mm gap cuvettes in the presence of oligonucleotides, subjected to 5 cycles of 20 V, 10 ms separated by 500-ms gaps in electroporation buffer (120 mM KCl, 0, 15 mM CaCl 2 , 10 mM K 2 HPO 4 /KH 2 PO 4 , 25 mM HEPES, 2 mM EGTA, 5 mM MgCl 2 , 50 mM glutathione, 2 mM ATP, pH 7.6). Cells were washed again and transferred to culture medium.
DC activation
MoDC were harvested at indicated times after transfection, washed twice in cytokine-free medium, and incubated at concentrations of 5 ϫ 10 5 cells/ml with human recombinant CD40L trimer (1 g/ml; a kind gift from Immunex), and IL-1␣ (3-10 ng/ml; R&D Systems) for 18 h. Cells were harvested, and supernatant fluid was collected and stored frozen at Ϫ20°C until tested.
RT-PCR analysis
Total RNA was extracted from 5 ϫ 10 5 DC using TRIzol reagent (Invitrogen, Cergy Pontoise, France). cDNA was synthesized using random hexamers, dNTP mixture, rRNAs in ribonuclease inhibitor, and SuperScript II Rnase H-Reverse Transcriptase (Invitrogen, San Diego, CA). PCR amplification was conducted in 50 l containing 1-5 l of cDNA, 1.5 mM MgCl 2 , dNTP mixture (0.2 mM each dNTP), 0.5 M each oligonucleotide primer, and 2 U of Taq DNA polymerase. Primers used were: p50 sense 5Ј-CTGGAAGCACGAATGACAGA, p50 anti-sense 5Ј-TTTCAAGTTG GATGCATTGG; cRel sense 5Ј-GCACAGCACAGACAACAACC, cRel antisense 5Ј-TCAGCTGTTTTTCAGGGACA (Invitrogen). ␤-Actin and human IL-12␤ (p40) primer pairs were from Ambion (Austin, TX) and R&D Systems, respectively. Amplification steps consisted of 35 cycles of denaturation at 94°C for 40 s, annealing at 55°C (␤-actin, p50, and cRel) or 57°C (IL-12p40) for 40 s, and extension at 72°C for 40 s using a DNA cycler (PerkinElmer, Wellesley, MA). PCR products (expected size 297 bp for p50, 299 bp for c-Rel, 294 bp for ␤-actin, and 559 bp for IL-12 p40) were analyzed on 2% agarose gel electrophoresis stained with ethidium bromide.
Western blot
After transfection and overnight activation, 5 ϫ 10 5 DC were lysed in 50 mM Tris, 150 mM NaCl, 1% Triton X 100, 1% sodium deoxycholate, 0.1% SDS, and 5 mM EDTA. Protease inhibitor mixture and pellets were kept at Ϫ80°C until used. Protein amounts were determined with the Bio-Rad DC Protein Assay (Bio-Rad, Hercules, CA). For each condition, 10 g of protein was separated on 10% polyacrylamide gels and transferred to nitrocellulose sheets. Binding with polyclonal goat Abs specific for p50 (Sc-1191, 1/100 dilution) or for ␤-actin (Sigma-Aldrich, St. Louis, MO) was revealed with peroxidase-conjugated rabbit anti-goat Abs (1/5000 dilution) using the ECL Western Blotting Analysis System (Amersham Pharmacia Biotech).
Immunofluorescence detection
A total of 0.5-1 ϫ 10 5 cells were spun on glass coverslips and fixed with 4% paraformaldehyde for 10 min at 4°C. Cells were washed twice in PBS and then permeabilized in saponin buffer (0.1% saponin, 0.2% BSA, 0.02% sodium azide, in PBS). Nonspecific Fc binding was blocked by 10 min of incubation with human ␥-globulin (1 mg/ml) and 1/100 dilution of donkey serum (Sigma-Aldrich). Polyclonal goat Abs specific for NF-B p50 (Sc-1191) (Santa Cruz Biotechnology, Santa Cruz, CA) were used at 5 g/ml and revealed by a FITC conjugated donkey anti-goat secondary reagent (Jackson ImmunoResearch Laboratories, West Grove, PA) used at 1/400 dilution in saponin buffer. Cell nuclei were stained with 4Ј,6Ј-diamidino-2-phenylindole (DAPI) included in the Vectashield mounting medium (Abcys, Paris, France). Cells were observed under epifluorescence microscopy, and cells expressing, or not, p50 protein in the nucleus above background stain were enumerated after analysis of Ͼ100 cells.
DNA-binding ELISA
DNA binding activity by p65, p50, and cRel, as well as c-Fos, CREB-1, and activating transcription factor 2 (ATF2) were detected by ELISA using the Mercury Transfactor Profiling kit (Inflammation 1; Clontech Laboratories, Palo Alto, CA). MoDC were transfected, and 3 days later they were activated with CD40L and IL-1. A total of 2 g (nuclear) or 3 g (cytosolic) proteins were tested for each transcription factor binding activity following manufacturer's instructions. Color development of tetramethylbenzidine substrate was measured at 630 nm using a Dynatech MR5000 plate reader (Dynatech Laboratories, Chantilly, VA).
Flow cytometric analysis
Directly conjugated mouse mAbs, including FITC-conjugated or APCconjugated anti-HLA-DR, PE-conjugated anti-human CD80, anti-CD83, anti-CD86 (BD PharMingen, San Diego, CA), anti CD1a (Caltag Laboratories, Burlingame, CA), and FITC-conjugated anti CD14 (3C10-1E12) were used according to a procedure described previously for detection of cell surface or intracellular Ags (26) . Detection of surface HLA-DR and intracellular CD83 was done by staining first for HLA-DR, then fixation, permeabilization, and intracellular staining for CD83. Cellular staining was measured on a FACSCalibur instrument (BD Biosciences, San Jose, CA), and data were analyzed using CellQuest or WinMDI (version 2.8) software, with results expressed as percentages of cells staining above background staining obtained with irrelevant mAbs.
Purification of T cells and MLR
Purified naive cord blood T cells (Ͼ95% CD3 ϩ T cells) were prepared by negative selection. MNC were incubated with mAbs specific for glycophorin A (10F7 MN), CD14 (3C10-1E12), CD32 (IV3), CD11b (OKM1), and CD40 (G28-5) (American Type Culture Collection, Manassas, VA) to remove red blood cells, phagocytes, B cells, and monocytes (Dynal Biotech, Lake Success, NY). Magnetic bead selection was repeated after the addition of anti-CD20 and anti-HLA-DR mAbs (Caltag Laboratories) to further remove B cell and APCs. MLR was set up by culturing purified naive T cells (5 ϫ 10 4 cells/0.2 ml of R10 medium per well in triplicate) with various concentrations of allogeneic transfected DC obtained ϳ30 h after transfection with the various siRNAs. Four to six days after initiation of MLR, a fraction of culture medium was harvested to measure the production of IFN-␥ by ELISA. Then, 1 Ci of [ 3 H]thymidine (NEN, Boston, MA) was added to each well during the last 10 h of culture to measure [ 3 H]thymidine incorporation using a liquid scintillation counter.
ELISA IL-12p70 (␣␤), IL-10, and IFN-␥ were measured in culture medium using the OptEIA ELISA sets according to manufacturer's instructions (BD PharMingen). Lower limits of detection were 8, 8, and 4 pg/ml, respectively. Human interferon-␣ levels were determined using specific ELISA kit (BioSource International, Camarillo, CA). The lower limit of detection was 25 pg/ml.
Results
Specific reduction of NF-B p50 mRNA and protein in immature DC
We used RNAi to assess the role of p50 in human MoDC because it is not known whether this constituent, which can either homodimerize or heterodimerize with RelB or cRel, has a specific role in human MoDC development. Transfection of small doublestranded RNA duplexes was tested as a way of performing lossof-function analysis in human MoDC in vitro. SiRNAs specific for human p50 mRNA were designed as described (20) , ensuring that they lacked significant sequence homologies by standard BLAST search with other known genes, including related family members. Irrelevant siRNAs with random sequences were used as specificity controls. Immature human MoDC were prepared by culture of adherent mobilized peripheral blood monocytes with GM-CSF and IL-4 and were electroporated with 150 nM of anti-p50 or control siRNAs. The choice of dose was based on preliminary experiments in fibroblast cell lines and based on reported methods for RNAi in cultured cell lines (22) . Twenty-four hours after transfection, RT-PCR analysis showed strong and specific down-regulation of p50 mRNA levels in cells treated with anti-p50 siRNAs, but not with control-irrelevant siRNA or in the absence of siRNA ( Fig. 1A) . Unlike p50, mRNAs of ␤-actin or of the family member cRel were not strongly affected. A separate, representative experiment shows the down-regulation of p50 protein by Western blot analysis of whole cell protein extracts ( Fig. 1B) , being about half the amount of untreated cells and about a third of those transfected with no siRNA or irrelevant siRNAs. These results show that p50 protein and mRNA can be effectively inhibited by transfection of siRNAs in cultured MoDC.
Lack of nonspecific toxicity and lack of induction of type-1 IFN
Double stranded RNA is known to elicit type-I IFN response in mammalian cells, leading to nonspecific arrest in transcription and cell death. However, because of their small size (Ͻ30 nt), siRNAs reportedly fail to activate the IFN-induced protein kinase R (27) and do not elicit a type-I IFN response in mammalian cells (21) . However, unlike other cell types, MoDC may be particularly apt at recognizing double-stranded RNA via the expression of Toll-like receptor 3 (28) , prompting us to assess toxicity or type-I IFN response. Electroporation of DC with control or anti-p50 siRNAs did not induce significant mortality with Ͼ90% of the cells, excluding trypan blue measured in seven experiments (data not shown). Using an ELISA specific for IFN-␣ and a bioassay measuring protection of WISH cells against the cytopathic effect of vesicular stomatitis virus, we failed to detect either IFN-␣ or type-I IFN activity in culture medium of DC transfected with control or anti-p50 siRNAs (data not shown). Thus, siRNAs are not toxic and do not induce type-I IFN response in MoDC.
RNAi prevents nuclear expression of p50 after activation
Like other family members, p50 exists in the cytoplasm in inactive form, bound to IB inhibitory proteins. In response to cellular activation, for instance the activation of MoDC with CD40L, the phosphorylation of IB and its degradation lead to accumulation of p50-containing complexes in the nucleus and sustained transcriptional activity (15) . In this study, we have used CD40L in combination with IL-1 to stimulate MoDC. This stimulus is known to trigger the secretion of high levels of IL-12 by DC and enables them to prime the differentiation of naive CD4 and CD8 T cells into type-1 effector cells (29, 30) . To test the role of p50 in this mode of activation, immature MoDC were treated with increasing concentrations of siRNAs before activation with CD40L ϩ IL-1. We observed a strong, specific, and dose-dependent inhibition of p50 mRNA levels at doses of 150 nM anti-p50 siRNA or higher ( Fig. 2A) . In immature MoDC, levels of p50 in the nucleus were very low (data not shown) but strongly up-regulated upon activation ( Fig. 2B ). This is consistent with increased p50-containing DNA binding activity reported in DC after treatment with proinflammatory agents including TNF-␣, IL-1, or CD40-L (12, 15) . Nuclear p50 expression examined by immunofluorescence was inhibited by anti-p50 siRNAs in a dose-dependent and specific manner ( Fig. 2B ). Maximal inhibition was obtained with concentrations Ն50 nM, concentrations that were strongly effective in six other separate experiments. Cells with p50 nuclear levels above background were enumerated in four such experiments, and pooled data in the range 50 -400 nM showed a mean percentage of cells expressing p50 in nucleus Ϯ SD of 82% Ϯ 8% in control-treated MoDC and 46% Ϯ 11% in anti-p50-treated MoDC. The difference was statistically significant ( p Ͻ 0.05, paired t test).
Transcriptional activity was evaluated by the binding of protein extracts to specific oligonucleotide probes. In activated MoDC, binding of p65, p50, ATF2, and cRel was detected in mock-transfected MoDC (Fig. 2C, 0) . That of p65, p50, or cRel was slightly reduced in cells transfected with control or irrelevant siRNAs, suggesting some level of nonspecific response to siRNAs. However, only anti-p50 siRNA transfection further down-regulated p50 binding, whereas that of p65, cRel, CREB-1, c-Fos, or ATF2 was similar in all cells treated with siRNAs. The cytosolic fraction also showed reduced p50 activity after anti-p50 siRNA transfection, which confirms an effect consistent with the overall reduction of the gene product. Transfection of MoDC with siRNAs directed against p50 achieved nontoxic, specific, and significant reduction in mRNA and protein expression in a dose range and manner consistent with RNAi. Such interference impaired p50 nuclear localization and DNA-binding activity in response to CD40L ϩ IL-1 activation, suggesting that transcription of p50 target genes could be impaired.
IL-12 production is reduced after p50 inhibition
IL-12 is a cytokine pivotal for the development of cellular immunity and for the production of high levels of IFN-␥ by T cells (31) . Biologically active IL-12␣␤ is a heterodimer produced from the transcription of separate genes regulated independently (31) . Prior results have shown that CD40L alone or in combination with IL-1 induces high levels of IL-12␤ transcription (32) . Thus, IL-12␤ mRNA levels were evaluated in MoDC activated with CD40L ϩ IL-1 after p50 interference using a standard RT-PCR technique. Two representative experiments of three shown in Fig. 3A strongly suggest that a reduction of IL-12␤ mRNA level is obtained after p50 interference. These results are consistent with studies of the promoter of the IL-12␤ gene, which is NF-B-inducible and contains sites for the binding of p50 and cRel in B cells (33) . At the protein level, we observed a reduction in the secretion of IL-12␣␤ heterodimer after transfection of anti-p50 siRNAs and in response to CD40L ϩ IL-1 activation, whereas the production of IL-10 Secretion of IL-12␣␤ was measured by ELISA in culture medium as described above. D, Same cells as above (Fig.  3C) were collected at different time points after activation and examined for p50 nuclear expression using immunofluorescence. Numbers of DAPI ϩ nuclei expressing p50 were counted, and results were expressed as percentages Ϯ SD of replicate counts.
FIGURE 2.
Inhibition of p50 mRNA, protein, and transcriptional activity in activated MoDC. A, MoDC were transfected with indicated doses of anti-p50 or Control I siRNAs, or no siRNA (0). Two hours later, cells were activated with CD40L ϩ IL-1 for a period of ϳ18 h, and total RNA was obtained for RT-PCR amplification using primers specific for ␤-actin and p50. Ethidium bromide agarose gel is representative of one experiment. B, Transfected MoDC, same as above, were activated as described, but 2 days after transfection. Cells were spun and fixed, and intracellular p50 expression was measured using immunofluorescence. DAPI staining was used to detect cell nuclei. C, Oligonucleotide-specific binding activity tested by ELISA in MoDC transfected with 200 nM indicated siRNAs and activated with CD40L ϩ IL-1 as described in Materials and Methods. One experiment. remained unchanged (Table I) . Cells treated with anti-p50 siRNAs produced ϳ5-30% of the IL-12 produced by cells treated with control siRNAs, which is a strong, albeit not complete, reduction. The inhibition was dose-dependent ( Fig. 3B ), visible at 10 nM, and optimal at or above 50 nM anti-p50 siRNAs. This inhibition in IL-12 production was well correlated to the dose-dependent inhibition of p50 nuclear protein that is documented in Fig. 2B . Although doses of 10 -50 nM siRNA inhibit p50 protein expression and IL-12 production, these do not appear sufficient to completely inhibit p50 mRNA levels ( Fig. 2A) . This apparent discrepancy can be explained by differences in sensitivity of the techniques and by different timing of analysis, as mRNA is examined shortly after electroporation, whereas p50 and IL-12 protein inhibition studies were done several days after electroporation.
Capacity for IL-12 production is temporally regulated in DC, being high in immature or freshly cultured cells and decreasing with time of culture or prolonged activation (our unpublished observations and Refs. 34 and 35) . To examine the effects of p50 interference on such temporal regulation, immature and transfected MoDC were activated at various times to measure IL-12 production. As expected, IL-12 production capacity decreased over time but was always strongly down-regulated after interference with p50. Levels were only 10% of control-activated MoDC cultures when cells were stimulated 3 days after transfection (Fig. 3C) . In a temporally correlated fashion, the expression of nuclear p50 was also blocked, being at its lowest 3 days after transfection (Fig. 3D) . Thus, the dose-and time-dependent correlation between p50 levels and IL-12 production and the effect on IL-12␤ mRNA levels clearly demonstrate that p50 is critically required in MoDC to regulate IL-12 production in response to CD40L ϩ IL-1.
Unchanged cell surface phenotype after p50 down-regulation
Maturation of MoDC induces rapid phenotypic changes. Our experiments used a homogeneous population of early immature MoDC obtained 4 days after adherence, and which had low levels of MHC class II or CD80, little CD86, and barely detectable expression of CD83 on the surface (Fig. 4A) . The great majority of these cells (ϳ90%) did not display CD14, but they were uniformly positive for CD1a on the surface and expressed intracellular CD83. These criteria, taken together with morphological appearance (data not shown), confirmed the DC nature of the cells studied (Fig. 4B) . A relatively short stimulation with CD40L ϩ IL-1 (overnight) induced clear, albeit not complete, maturation that was also accompanied by high levels of IL-12 secretion. Compared with unstimulated cells, maturation was evident by the up-regulation of MHC class II levels on the surface, up-regulation of intracellular CD83 levels (Fig. 4B) , up-regulation of CD80 and CD86 levels, and the expression of cell surface CD83 on the majority of the cells (Ͼ60%) (Fig. 4A) . Collectively, phenotypic maturation changes of MoDC seem to require normal levels of NF-B activity, because they are impaired in proteasome blocking studies (13) . However, it is not known whether p50 plays a specific role in this process. In this study, we show with flow cytometry that basal or activationinduced expression of cell surface molecules was not affected by the transfection procedure or by transfection with irrelevant siRNAs (Fig. 4 and data not shown). Interference with p50 did not change basal or activation-induced expression of CD80, CD86, HLA-DR, and CD83 on MoDC in the timeframe examined ( Fig. 4) . Levels of CD40 were unchanged (data not shown). These results suggest that p50 is not critically required for the maintenance of basal or activation-induced cell surface phenotype of MoDC.
T cell stimulating ability after p50 interference
The processes of phenotypic maturation and induction of IL-12 production by MoDC are thought to enable effective priming of a Immature MoDC were transfected with anti-p50 siRNAs, control siRNAs, or no siRNA (0) and tested Ϸ2 days after transfection for their ability to produce IL-12 and IL-10 in response to CD40L ϩ IL-1 (two middle columns) or for their ability to induce the production of IFN-␥ in MLR (last two columns on the right).
b Immature MoDC were activated overnight with CD40L and IL-1. Culture medium was harvested, and IL-12␣␤ and IL-10 were measured by ELISA. Paired t test between Control I siRNA and anti-p50 siRNA for IL-12␣␤ ( p ϭ 0.04), IL-10 (NS).
c Immature MoDC were cocultured with purified allogeneic cord blood T cells at the ratio of 1-2% DC per T cell. Culture medium was harvested 5-7 days later, and IFN-␥ production was measured by ELISA. Average inhibition by anti-p50 siRNA compared to control siRNA is 54%, significant by paired t test (p ϭ 0.005). When indicated, secondary MLR was performed by restimulating T cells with irradiated MNC from the MoDC donor. ND, not done. Th1 T cell development (1) . In this study, we observed that interference with p50 affected the production of IL-12, but not phenotypic maturation, prompting us to evaluate the consequences on T cell-stimulating activity. Immature MoDC transfected with siRNAs were used to stimulate allogeneic naive cord blood T cells. Interference with p50 did not change the induction of T cell pro-liferation ( Fig. 5A ), which seems consistent with a lack of effect on MHC class II Ags and costimulatory molecule expression in this response dominated by CD4 ϩ T cell proliferation. Yet we observed a significant reduction in the production of IFN-␥ in these T cell cultures (Fig. 5B) , particularly when the levels were low, as when suboptimal numbers of DC (5 and 1% of the T cells) were present in the culture. Table I shows the correlation between IL-12 production analysis and induction of IFN-␥ in MLR under a suboptimal Ag-presenting condition. Results on average show a 50% reduction in IFN-␥ levels, which is significant and consistent with reduced IL-12 production capacity. At the present time, we cannot exclude that other T cell properties are affected or that p50 interference has effects other than on IL-12 that could also have an impact on T cell development. This will have to be examined in future studies. Thus, p50 is important for MoDC activation, regulating the production of IL-12 and being required for optimal induction of Th1 T cell responses.
Discussion
Using siRNAs, we assigned a critical role for p50 in IL-12 production, but not in the up-regulation of cell surface molecule in the response of MoDC to CD40L ϩ IL-1. The observed effect on the down-regulation of p50 mRNA and protein is consistent with the proposed mechanism of action and with the specificity of RNAi. RNAi is mediated by RNA duplexes bound to a protein complex called RNA-induced silencing complex, guided by siRNA to accomplish the specific recognition of homologous mRNA sequences and subsequent degradation by nucleases (16 -18) . Previous studies have effectively used this approach in various cell lines as well as in primary T and B lymphocytes to knock down a variety of structural, motor, nuclear, or even viral proteins with essential or nonessential function (19, 20, (23) (24) (25) . These studies as well as our own results find that the technique is not toxic. The effects appear to be specific and last over several days, a period of time sufficient to measure phenotypic changes in the cells. However, all studies report incomplete inhibition of protein, and thus the technique is considered to be a knockdown. There are several possibilities to explain the partial effect, including dose and kinetics, technical considerations, suboptimal design of the effector siRNA, persistence of protein, and mRNA after transfection and limitations in formation or function of the RNA-induced silencing complex. Yet, many of the observed effects of protein knockdown appear to be similar to those observed after genetic mutations where targeted proteins are absent (20) .
We observed one functional consequence of p50 targeting, which is the down-regulation of IL-12 production in response to CD40L ϩ IL-1. Assigning a role for p50 in the control of IL-12 production by human DC is novel. Murine studies had not reported a major role for p50 alone in the control of DC function, as it was found that IL-12p40 mRNA could be up-regulated in response to LPS activation in p50 Ϫ/Ϫ mice (10) . However, secretion of the biologically active IL-12 heterodimer was not examined in this study. A separate study of endotoxin tolerance found a reduced IL-12p70 in serum or splenocytes of LPS-treated p50 Ϫ/Ϫ mice compared with controls (36), suggesting that p50 could possibly play a nonredundant role in the control of IL-12 production by murine DC. Our results clearly demonstrate that this is the case in human MoDC. The requirement for p50 in IL-12 production may be specific of MoDC or of the signaling pathways engaged by the mode of activation that was used. Possibly, changes other than those related to T cell stimulation may be induced by p50 targeting, warranting further analysis of p50 deficiency in APCs. With the reduced production of IL-12 in MoDC, we find a reduction in T cell IFN-␥ in MLR that was expected given the biological effects of IL-12 (31) . Although the effects on IFN-␥ were modest in our experimental system, these findings may have relevance for pathogenicity, because it was shown that p50 Ϫ/Ϫ animals are resistant to the induction of experimental autoimmune encephalomyelitis (37) . It is known that the combined lack of p50 and cRel strongly impairs IL-12␤ transcription and IL-12␣␤ secretion (10) . This prompted us to evaluate cRel activity in our system. RT-PCR and DNA-binding analysis showed that it was not dramatically affected, suggesting that the reduction in IL-12 production appears to be the direct result of RNAi on p50 in MoDC. However, we cannot exclude that minimal effects on c-Rel or other family members could synergize and inhibit IL-12 production.
In contrast to IL-12, we found no consequence of p50 targeting on the up-regulation of MHC or costimulatory cell surface Ags in our system. Such cell surface phenotypic changes are globally NF-B-dependent (13, 15 ), suggesting functional redundancy or involvement of other NF-B subunits. Studies with B cell lines transfected with antisense oligonucleotides have implicated RelB in the control of up-regulation of MHC class II Ags in these cells (38) . These results highlight how RNAi can be used to specifically analyze the role of single gene products, which in the case of NF-B signaling studies is advantageous over global pathway inhibition methods. Furthermore, unlike antisense oligodeoxyribonucleotides, siRNAs appear to require doses 10-to 100-fold inferior to show a similar effect (Ref. 39 and our unpublished data). Our results constitute a first report of a phenotype induced by RNAi in human DC and show that further studies can be envisioned to expand the application of RNAi in human cells to improve our understanding of Ag presentation and immune responses.
